Skip to main
CAPR
CAPR logo

Capricor Therapeutics (CAPR) Stock Forecast & Price Target

Capricor Therapeutics (CAPR) Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 70%
Buy 30%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Capricor Therapeutics Inc. demonstrates a positive outlook driven by the promising results of deramiocel, which has shown long-term safety and therapeutic durability without new safety signals, solidifying its favorable risk-benefit profile. The company is positioned for accelerated commercialization in Europe and the U.S. due to strategic partnerships that enhance pre-commercial activities and support manufacturing scale-up. Additionally, by focusing on DMD-cardiomyopathy, Capricor is effectively de-risking its Biologics License Application (BLA) submission plans, indicating potential for a faster path to market.

Bears say

Capricor Therapeutics Inc. faces a negative outlook primarily due to the inconclusive results of its clinical trials, specifically regarding deramiocel, which demonstrated only a modest reduction in disease progression over three years, with patients showing an average decline in the Performance of the Upper Limb 2.0 score. Additionally, the decline in the external comparator group raises concerns about the effectiveness of the treatment, as indicated by a statistically significant 7.19-point drop. Financially, the company's ability to advance its drug development is further threatened by potential difficulties in securing adequate funding, which could severely limit its operational progress and market presence.

Capricor Therapeutics (CAPR) has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 70% of analysts recommend a Strong Buy, 30% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Capricor Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Capricor Therapeutics (CAPR) Forecast

Analysts have given Capricor Therapeutics (CAPR) a Strong Buy based on their latest research and market trends.

According to 10 analysts, Capricor Therapeutics (CAPR) has a Strong Buy consensus rating as of Jul 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Capricor Therapeutics (CAPR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.